The rare autoimmune disorder generalized myasthenia gravis can cause muscle weakness in the limbs and face.
Patient support programs (PSPs) for individuals with generalized myasthenia gravis (gMG) ought to use a targeted approach to provide services to those experiencing social determinants of health (SDOH) barriers, new survey results suggest. This is especially true for populations who are harder to reach populations, authors noted.
Findings were published in Frontiers in Public Health.
The rare autoimmune disorder gMG causes patients to experience debilitating muscle weakness, the researchers explained. It is most common in women younger than age 40 and men older than age 60 and affects over 50,000 Americans.
Although treatments to manage gMG can be effective, up to 20% of patients with gMG will experience a myasthenic crisis that requires intensive care and respiratory support. In addition, common conditions like diabetes and hypertension can compound the symptoms of gMG.
“Critically, a major knowledge gap exists in understanding the burden and impact SDOH, defined as nonmedical, nonbiological, and nongenetic factors of the environment or individuals’ lives that affect health, functioning, and HRQOL [health-related quality of life] outcomes—including conditions in which people are born, grow, work, live, and age—in gMG,” the authors wrote.
They carried out a sequential mixed-methods study to better understand how SDOH barriers affect patients with diverse backgrounds. Specifically, they wanted to assess patients during 4 phases of the disease: diagnosis, treatment access, treatment initiation, and treatment continuation.
Fifteen individuals completed a double-blind qualitative web-assisted phone interview that lasted 45 minutes. Most participants were people of color, were unemployed, had a low income, and were enrolled in public insurance. Eleven participants were patients, 2 were caregivers, and 2 were representatives of PSPs.
Among those living with the condition and experiencing SDOH barriers, financial and mental health concerns were the most reported throughout all disease phases. Participants also reported experiencing barriers like navigating insurance coverage and maintaining a job during their diagnosis and treatment of the disease.
“Awareness and utilization of existing support services were low, especially when accessing treatment,” the authors wrote.
“Educational, financial, and personalized support with high ‘human touch’ were commonly perceived as the most valuable resources,” they added.
Participants also held nurse case managers in high regard, as these individuals can assist with disease education and tracking symptoms. However, utilization of these services was low.
Thirty-eight individuals completed a quantitative survey. Seventy-six percent of these patients reported issues making ends meet at the end of each month. Half also expressed concerns about stable housing.
Taken together, the researchers suggest underrepresented communities with gMG should undergo mental health monitoring on a consistent basis. In addition, more research should be carried out to explore and address the potential systemic barriers to access to care in this population. They also suggest efforts to boost awareness and utilization of existing support services can be useful for these patients, along with disseminating high-quality educational resources using a multichannel approach.
Findings of the current study may only apply to the general population of patients living with gMG, marking a limitation. The researchers also mainly used web-based data collection, which may have introduced bias for digital literacy.
“To improve the experiences of historically marginalized individuals in the health care system, the larger gMG support network should continue to spotlight these communities to work together to provide further evolved customized and localized support focused on the specific needs of these communities,” the authors concluded.
Reference
Hughes T, Anderson AEL, Habib AA, et al. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. Published online May 19, 2023. doi:10.3389/fpubh.2023.1147489
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More